Drug Trial Radar · NCT05288023
Azithromycin for Child Survival in Niger: Programmatic Trial (AVENIR)
Last checked: Nov 19, 2026Latest source record: Mar 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
169,707
Actual
Start
Dec 1, 2022
Primary completion
Jan 15, 2024
Study completion Jan 15, 2024
Sponsor
- Lead sponsor
- University of California, San FranciscoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Bill and Melinda Gates Foundation; Ministry of Health, Niger
- First posted
- Mar 18, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 month
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The MORDOR trial found that biannual distribution of azithromycin to children 1-59 months old reduced child mortality. The World Health Organization (WHO) released conditional guidelines for this intervention, which include targeting azithromycin distributions to children 1-11 months of age in high mortality settings. The proposed trial aims to demonstrate and evaluate large-scale implementation of azithromycin to children aged 1-11 months old in the context of a programmatic setting while monitoring mortality and resistance antimicrobial resistance.
Conditions
- Resistance Bacterial
- Morality
- Child Health
- Implementation
Interventions
Azithromycin for Oral SuspensionDrug
Azithromycin will be administered as a single dose in oral suspension form for children (up to the maximum adult dose of 1g). Dosage will be calculated by age for children aged 1-5 months. For children 6-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Prevalence of Genetic Determinants of Macrolide Resistance From Population-based SamplesTime frame: 2 years
- Load of Genetic Determinants of Macrolide Resistance From Population-based SamplesTime frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Proctor foundation
San Francisco, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.